#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

The risks of legalizing cannabis drugs


Authors: L. Csémy;  K. Nešpor
Authors‘ workplace: Ředitelka: MUDr. Zuzana Barboríková, MBA ;  Psychiatrická nemocnice Bohnice, Praha
Published in: Prakt. Lék. 2023; 103(1): 32-34
Category: Of different specialties

Overview

The factual legalization of cannabis drugs would lead to higher consumption and a decrease in the prices of cannabis drugs on the black market. This would bring a host of complications including foetal harm, mental disorders, traffic accidents and economic losses.

Keywords:

Marijuana – cannabis – risks – legalization


Sources

1. Bouquet E, Pain S, Eiden C, et al. Adverse events of recreational cannabis use reported to the French addictovigilance network (2012–2017). Br J Clin Pharmacol 2021; 87(10): 3925–3937.

2. Crocker CE, Carter AJE, Emsley JG, et al. When cannabis use goes wrong: mental health side effects of cannabis use that present to emergency services. Front Psychiatry 2021; 12: 640222.

3. Dahlgren MK, Sagar KA, Smith RT, et al. Recreational cannabis use impairs driving performance in the absence of acute intoxication. Drug Alcohol Depend 2020; 208: 107771.

4. Dellazizzo L, Potvin S, Dou BY, et al. Association between the use of cannabis and physical violence in youths: a meta-analytical investigation. Am J Psychiatry 2020; 177(7): 619–626.

5. Diep C, Bhat V, Wijeysundera DN, et al. The association between recent cannabis use and suicidal ideation in adults: a population- based analysis of the NHANES from 2005 to 2018. Can J Psychiatry 2022; 67(4): 259–267.

6. Fischer B, Lee A, O‘Keefe-Markman C, Hall W. Initial indicators of the public health impacts of non-medical cannabis legalization in Canada. EClinicalMedicine 2020; 20: 100294.

7. Gesterling L, Bradford H. Cannabis use in pregnancy: a state of the science review. J Midwifery Womens Health 2022; 67(3): 305–313.

8. Goyal H, Awad HH, Ghali JK. Role of cannabis in cardiovascular disorders. J Thorac Dis 2017; 7: 2079–2092.

9. Grundy Q, Imahori D, Mahajan S, et al. Cannabis companies and the sponsorship of scientific research: A cross-sectional Canadian case study. PLoS One 2023; 18(1): e0280110.

10. Gunadi C, Zhu B, Shi Y. Recreational cannabis legalization and transitions in cannabis use: findings from a nationally representative longitudinal cohort in the United States. Addiction 2022; 117(10): 2651–2659.

11. Hengartner MP, Angst J, Ajdacic-Gross V, Rössler W. Cannabis use during adolescence and the occurrence of depression, suižencidality and anxiety disorder across adulthood: Findings from a longitudinal cohort study over 30 years. J Affect Disord 2020; 272: 98–103.

12. Chomynová P, Grohmannová K, Dvořáková Z. Zpráva o nelegálních drogách v České republice 2022. Úřad vlády České republiky 2022; 246.

13. Imtiaz S, Nigatu YT, Ali F, et al. Cannabis legalization and cannabis use, daily cannabis use and cannabis-related problems among adults in Ontario, Canada (2001–2019). Drug Alcohol Depend 2023; 244: 109765.

14. Kim C, Chum A, Nielsen A, et al. Associations between recreational cannabis legalization and cannabis-related emergency department visits by age, gender, and geographic status in Ontario, Canada: An interrupted time series study. PLoS One 2022; 17(10): e0268718.

15. Kimbrel NA, Meyer EC, DeBeer BB, et al. The impact of cannabis use disorder on suicidal and nonsuicidal self-injury in iraq/afghanistan- era veterans with and without mental health disorders. Suicide Life Threat Behav 2018; 48(2): 140–148.

16. Lalli M, Brouillette K, Kapczinski F, de Azevedo Cardoso T. Substance use as a risk factor for bipolar disorder: A systematic review. J Psychiatr Res 2021; 144: 285–295.

17. Lin AL, Nah G, Tang JJ, et al. Cannabis, cocaine, methamphetamine, and opiates increase the risk of incident atrial fibrillation. Eur Heart J 2022; 43(47): 4933–4942.

18. Luke S, Hobbs AJ, Smith M, et al. National Maternal Cannabis Working Group. Cannabis use in pregnancy and maternal and infant outcomes: A Canadian cross-jurisdictional population-based cohort study. PLoS One 2022; 17(11): e0276824.

19. Matheson J, Le Foll B. Cannabis legalization and acute harm from high potency cannabis products: a narrative review and recommendations for public health. Front Psychiatry 2020; 11: 591979.

20. Myran DT, Tanuseputro P, Auger N, et al. Pediatric hospitalizations for unintentional cannabis poisonings and all-cause poisonings associated with edible cannabis product legalization and sales in Canada. JAMA Health Forum 2023; 4(1): e225041.

21. Nešpor K. Marihuana, paměť, soustředění a rozhodování u starších osob. 2023 [online]. Dostupné z: www.drnespor.eu/ THCEld3.doc [cit. 2023-01-31].

22. O‘Grady MA, Iverson MG, Suleiman AO, Rhee TG. Is legalization of recreational cannabis associated with levels of use and cannabis use disorder among youth in the United States? A rapid systematic review. Eur Child Adolesc Psychiatry 2022 May 4. [Epub ahead of print]. PMID: 35508822.

23. Shah R, Ghosh A, Avasthi A, et al. White matter microstructure and gray matter volume in cannabis-induced psychosis and schizophrenia with cannabis use. J Neuropsychiatry Clin Neurosci 2022; 34(4): 406–413.

24. Vaucher J, Keating BJ, Lasserre AM, et al. Cannabis use and risk of schizophrenia: a Mendelian randomization study. Mol Psychiatry 2018; 23(5): 1287–1292.

25. Wilson S, Rhee SH. Causal effects of cannabis legalization on parents, parenting, and children: A systematic review. Prev Med 2022; 156: 106956.

Labels
General practitioner for children and adolescents General practitioner for adults
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#